Adam Koppel - 16 Apr 2026 Form 4 Insider Report for Kailera Therapeutics, Inc. (KLRA)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: KLRA
Reported as of: 16 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Apr 2026, 18:08:42 UTC
Prior SEC filing: 30 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Adam Koppel

Key filing fact

Adam Koppel filed Form 4 for Kailera Therapeutics, Inc. (KLRA) on 20 Apr 2026.

Key facts

This page summarizes Adam Koppel's Form 4 filing for Kailera Therapeutics, Inc. (KLRA).
6 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 20 Apr 2026, 18:08.

Change

Previous filing in this sequence was filed on 30 Dec 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001578965 Primary reporting owner

Koppel Adam

Relationship: Director, 10%+ Owner
Address: C/O BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC 200 CLARENDON STREET, BOSTON
Signature: /s/ Adam Koppel
Signature date: 20 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KLRA transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +16,875,000
Change %
Price
Shares after: 16,875,000
Date: 20 Apr 2026
Ownership: See footnotes
Footnotes: F1, F4, F5

KLRA transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +4,145,768
Change %: +25%
Price
Shares after: 21,020,768
Date: 20 Apr 2026
Ownership: See footnotes
Footnotes: F2, F4, F5

KLRA transaction

Common Stock

Purchase

Transaction value
Shares: +1,562,500
Change %: +7.4%
Price: $16.00^*
Shares after: 22,583,268
Date: 20 Apr 2026
Ownership: See footnotes
Footnotes: F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KLRA transaction Derivative

Series A-1 Preferred Stock

Conversion of derivative security

Transaction value
Shares: -16,875,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 20 Apr 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 16,875,000
Exercise price
Footnotes: F1, F4, F5

KLRA transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -4,145,768
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 20 Apr 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 4,145,768
Exercise price
Footnotes: F2, F4, F5

KLRA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +38,300
Change %
Price: $0.000000^*
Shares after: 38,300
Date: 16 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 38,300
Exercise price: $16.00
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.

Footnote F2

Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.

Footnote F3

The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to Dr. Koppel's continued service through each such vesting date.

Footnote F4

Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments").

Footnote F5

Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC ("BCLSI"). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.